Opinion Article - Pharmaceutical Bioprocessing (2021) Volume 9, Issue 4

Role of Bio Pharmaceuticals in Living Sources

*Corresponding Author:
Ravi Singh
Division of Biotechnology and Phycology, CSIR-Central Salt and Marine Chemicals Research Institute,Bhavnagar, India
E-mail: [email protected]

A biopharmaceutical, also referred to as a biologic(al) medical product or biologic, is any pharmaceutical drug product manufactured in, extracted from, or semisynthesized from biological sources. Different from totally synthesized pharmaceuticals, they include vaccines, blood , blood components, allergenics, somatic cells, gene therapies, tissues, recombinant therapeutic protein, and living medicines utilized in cell therapy. Biologics are often composed of sugars, proteins, nucleic acids, or complex combinations of those substances, or could also be living cells or tissues. They (or their precursors or components) are isolated from living sources—human, animal, plant, fungal, or microbial. They will be utilized in both human and animal medicine.

Terminology surrounding biopharmaceuticals varies between groups and entities, with different terms pertaining to different subsets of therapeutics within the overall biopharmaceutical category. Some regulatory agencies use the terms biological medicinal products or therapeutic biological product to refer specifically to engineered macromolecular products like protein- and nucleic acid-based drugs, distinguishing them from products like blood, blood components, or vaccines, which are usually extracted directly from a biological source. Specialty drugs, a recent classification of pharmaceuticals, are high-cost drugs that are often biologics. the ecu Medicines Agency uses the term advanced therapy medicinal products (ATMPs) for medicines for human use that are “based on genes, cells, or tissue engineering”, including gene therapy medicines, somatic-cell therapy medicines, tissue-engineered medicines, and combinations thereof. Within EMA contexts, the term advanced therapies refers specifically to ATMPs, although that term is quite nonspecific outside those contexts.

Gene-based and cellular biologics, for instance, often are at the forefront of biomedicine and biomedical research, and should be wont to treat a spread of medical conditions that no other treatments are available.

In some jurisdictions, biologics are regulated via different pathways from other small molecule drugs and medical devices.

Biopharmaceutics is pharmaceutics that works with biopharmaceuticals. Biopharmacology is that the branch of pharmacology that studies biopharmaceuticals.


With the expiration of various patents for blockbuster biologics between 2012 and 2019, the interest in biosimilar production, i.e., follow-on biologics, has increased. Compared to small molecules that contains chemically identical active ingredients, biologics are vastly more complex and contains a mess of subspecies. thanks to their heterogeneity and therefore the high process sensitivity, originators and follow-on biosimilars will exhibit variability in specific variants over time, however the security and clinical performance of both originator and biosimilar biopharmaceuticals must remain equivalent throughout their lifecycle. Process variations are monitored by modern analytical tools (e.g., liquid chromatography, immunoassays, mass spectrometry, etc.) and describe a singular design space for every biologic.

Thus, biosimilars require a special regulatory framework compared to small-molecule generics. Legislation within the 21st century has addressed this by recognizing an intermediate ground of testing for biosimilars. The filing pathway requires more testing than for small-molecule generics, but less testing than for registering completely new therapeutics.

In 2003, the ecu Medicines Agency introduced an adapted pathway for biosimilars, termed similar biological medicinal products. This pathway is predicated on a radical demonstration of “comparability” of the “similar” product to an existing approved product. Within the us , the Patient Protection and Affordable Care Act of 2010 created an abbreviated approval pathway for biological products shown to be biosimilar to, or interchangeable with, an FDA-licensed reference biological product. a serious hope linked to the introduction of biosimilars may be a reduction of costs to the patients and therefore the healthcare system.